毕赤酵母表达的含前S1、前S2和S表位乙肝表面抗原疫苗的制备和免疫原性研究

整合了乙肝表面抗原嵌合基因SS1和SS2的毕赤酵母工程菌株GS115-SS1S2经高密度发酵培养,甲醇诱导,抗原表达量达到300~600mg/L发酵液。SS1S2抗原经细胞破碎、硅胶吸附、疏水层析和凝胶过滤纯化,纯度达99%以上,每升培养物可收获纯化抗原82mg。纯化的SS1S2抗原经Al(OH)3吸附,在NIH小鼠中进行免疫效果评价。三组NIH雌性小鼠,分别腹腔接种2.5μg、0.625μg和0.156μgSS1S2疫苗或商品化的单S疫苗。部分小鼠在30天时采血,测定各疫苗组的ED50值。在SS1S2疫苗组,前S1、前S2和S抗原的ED50值分别为0.46、0.29和0.84μg,而S疫苗组S抗原的ED50为0.99μg。另一部分小鼠分别在7天和14天时采血,考察抗体阳转率与时间的关系。SS1S2疫苗前S1、前S2抗体阳转率在7d和14d时比S抗体的阳转率为高,提示前S抗体出现的时间较早。上述结果显示SS1S2疫苗比单S疫苗具有更好的免疫原性。     

恶性疟原虫pfs25多拷贝基因在毕赤酵母中的表达分析

目的:对恶性疟原虫pfs25的多拷贝基因重组菌株在毕赤酵母中进行表达分析,研究基因拷贝数对Pfs25蛋白表达量的影响。方法:构建重组质粒pAO815-αpfs25,利用BglⅡ-BamHⅠ同尾酶的特点,将基因表达框AOX1-αpfs25-AOX1(TT)插入到单拷贝表达质粒,依次重复,构建多拷贝重组质粒pAO815-(αpfs25)n,线性化后电转化毕赤酵母GS115,用MD平板筛选并进行表达分析。结果:构建得到1、2、3、4、5、6、7、8、10、12和14个pfs25基因拷贝的重组菌株,8拷贝pfs25基因的重组菌株表达量最高。结论:成功得到了pfs25基因的多拷贝表达重组菌株,经分析,多拷贝pfs25基因的目的蛋白表达量与其拷贝数并不呈线性正相关。     

白细胞介素-21与乙型肝炎病毒前S2S抗原融合蛋白在293T细胞中的表达

目的:构建白细胞介素-21(interleukin-21,IL-21)和乙型肝炎病毒前S2S抗原(S2S)的融合表达质粒,并研究其在293T细胞中的表达。方法:采用PCR方法扩增IL-21和HBV前S2S基因片段,分别克隆入pcDNA3真核表达质粒,用分子克隆方法构建融合表达质粒,并以脂质体2000转染293T细胞,分别应用ELISA法和Western Blot法检测细胞上清及细胞中IL-21和HBsAg的表达水平。结果:经酶切鉴定及DNA序列证实重组质粒内插入片段序列正确,三种重组质粒分别命名为pcDNA-IL-21、pcDNA-S2S和pcDNA-IL-21-S2S,并且重组质粒能在293T细胞内表达并分泌相关蛋白。结论:成功构建IL-21和乙型肝炎病毒前S2S抗原的融合表达质粒,重组质粒能在真核细胞内表达。     

乙型肝炎病毒PreS2S基因在毕赤酵母中表达的研究

构建重组质粒PHIL-D2/PreS2S以研究乙肝病毒PreS2(120-146)S基因编码蛋白在毕赤酵母中的表达。通过PCR扩增获得PreS2S片段,插入含AOX1启动子的Pichia Pastoris表达载体PHIL-D2中,构建重组表达质粒PHIL-D2/PreS2S,转化酵母宿主菌GS115。挑取阳性克隆摇床培养,甲醇诱导表达。通过ELISA、RPHA鉴定表达产物。成功构建了PHIL-D2/PreS2S真核表达载体,经过序列分析,插入的基因为在中国流行的adr亚型。在毕赤酵母中重组载体表达了S蛋白,S蛋白的表达量为34.9 mg/L,PreS2抗原检测为强阳性。利用毕赤酵母表达系统能够有效地表达乙型肝炎病毒的PreS2S蛋白,PreS2S蛋白具有良好的生物学活性。     

分泌型乙型肝炎病毒包膜M蛋白在毕赤酵母中的表达

将乙肝病毒包膜中蛋白M基因插入酵母整合型表达质粒pAO818的醇氧化酶 (AOX1)启动子下游 ,构建携带 8拷贝M表达盒的重组载体 ,经电穿孔转化SMD116 8菌株和G4 18筛选 ,得到了高效分泌表达M蛋白的毕赤酵母菌株 ,表达量超过 5 0mg L .经初步纯化 ,对表达产物的性质鉴定表明 ,重组蛋白具有preS2和S抗原性 ,可以形成颗粒 ,并具有一定程度的糖基化 .所构建的稳定重组菌株和所得到的重组蛋白颗粒 ,为进一步研究新一代的疫苗提供了必要的材料 .     

戊型肝炎病毒多拷贝重组质粒的构建及在毕赤酵母中的表达

目的体外构建戊型肝炎病毒(HEV)ORF2128-660多拷贝重组表达质粒,以提高HEVORF2128-660在毕赤酵母中的表达水平。方法采用PCR技术扩增目的基因ORF2128-660(E),然后将ORF2128-660(E)同义点突变为ORF2128-660,构建重组表达质粒ORF212 8-660/p AO815(单拷贝),Bam HⅠ和BglⅡ双酶切获得的目的基因表达盒(AOX-ORF2128-660)插入去磷酸化的质粒ORF2128-660/p AO815,得到2(AOX-ORF2128-660)/p AO815(2拷贝)质粒。重复上述方法依次构建3(AOX-ORF2128-660)/p AO815(3拷贝)、4(AOX-ORF2128-660)/p AO815(4拷贝)等多拷贝重组质粒。得到的多拷贝重组质粒电转化毕赤酵母菌GS115,甲醇诱导表达,SDS-PAGE分析比较不同拷贝数转化子的表达产量,ELISA检测表达产物的生物活性。结果构建了戊型肝炎病毒(HEV)ORF2128-660多拷贝重组表达质粒,表达的目的蛋白相对分子质量约为59 000,4拷贝重组质粒表达水平高于其他拷贝数重组质粒表达水平。结论成功构建了HEVORF2128-660多拷贝表达质粒,提高了其在毕赤酵母中的表达水平。     

adr亚型乙型肝炎病毒DNA的酶切图谱分析

<正> 本文报道以pAT153质粒为载体克隆的adr亚型乙型肝炎病毒(HBV)全基因的限制性内切酶图谱。重组质粒已命名为pHBV-NCl。重组质粒的提取和酶解采用常规方法。限制性内切酶为Bio-Labs公司产品。用Sepharcry S-1000纯化得到的质粒,经电泳鉴定都是完整的超螺旋DNA。经过鉴定其BamHⅠ、XhoⅠ、XbaⅠ、SstⅡ、SphⅠ、BglⅠ、BglⅡ、BstEⅡ、AceⅠ、AvaⅠ、HincⅡ、HpaⅠ等12种酶的21个切口已被定位。其中XhoⅠ、XbaⅠ、SstⅡ、     

一种多拷贝毕赤酵母表达载体的构建及人脑源性神经营养因子的表达

利用PCR技术扩增出pPIC9K载体的HIS4 Kan序列片段 ,与pPICZα重组 ,构建结合了两个载体特点的适合体外构建多拷贝基因表达盒的毕赤酵母表达载体pPICZα1,改造后的载体含HIS4 Kan序列 ,能整合到酵母染色体上 ,具有筛选方便、外源基因多拷贝组建迅速、蛋白产物分泌表达和易纯化等优点。将人脑源性神经营养因子(hBDNF)的cDNA(35 7bp)克隆入载体pPICZα1,利用同尾酶BglⅡ、BamHⅠ不可逆连接方式 ,分别构建含有 1、2、3、6个拷贝hBDNF表达盒的重组表达载体 ,电击法转化毕赤酵母GS115菌株 ,用G4 18和Zeocin筛选转化子 ,筛选到的阳性转化子用 0 5 %甲醇诱导 ,获得分泌型表达。表达产物类似于天然神经营养因子单体大小、分子量约 14kD。多拷贝hBDNF表达盒的表达水平亦高于单拷贝hBDNF表达盒 ,ELISA和Westernblot检测表明 :表达的蛋白能与鸡抗人脑源性神经营养因子抗体特异结合 ,证实该表达蛋白具有hBDNF的免疫原性     

乙型肝炎病毒S-preS1-C融合基因在酵母中的表达及抗原性分析

以HBV全基因组质粒为模板,扩增出目的区段:S(1-222AA),preS1(10-50AA)和C(2-30AA),以酶切-PCR的方法进行连接,克隆入表达载体pPIC3.5k,电穿孔转化后利用G418加压筛选出多拷贝整合菌株,诱导表达并对表达产物进行检测。结果显示融合后的基因为ss1c,长度约为906bp。在酵母中成功地进行了表达,表达产物(SSIC)的大小约为31kDa,并形成直径约为22nm的病毒样颗粒。表达产物与HBs抗体、preS1抗体和HBc抗体均有特异反应。为进一步研究治疗性疫苗提供了重要的基础。     

Immunogenicity of recombinant hepatitis B virus surface antigen fused with preS1 epitopes expressed in rice seeds

To test the possibility of producing a novel hepatitis B vaccine in plants, the modified hepatitis B virus (HBV) surface antigen (HBsAg) gene SS1 was expressed in rice under the control of the seed-specific Glub-4 promoter. The SS1 gene encodes a fusion protein consisting of amino acids 21-47 of the hepatocyte receptor-binding presurface 1 region (preS1) fused to the truncated C-terminus of the major HBV surface (S) protein. The production of antibodies against the preS1 region acts to protect humans against HBV infection by preventing HBV from binding to hepatocytes. The presence of SS1 in the genome of transgenic rice was confirmed by PCR and Southern blot analysis, and RNA dot blot analysis indicated that the fused SS1 gene was specifically expressed in rice seeds, with the highest expression level being about 31.5 ng/g dry weight grain. Western blot analysis revealed that the recombinant SS1 protein could be specifically recognized by both an anti-S protein antibody and an anti-preS1 antibody. The recombinant SS1 protein was also observed to form virus-like particles with a diameter of about 22 nm and a density of 1.25 g cm(-3). Furthermore, immunological responses against both the S and preS1 epitopes were induced in BALB/c mice immunized with the recombinant SS1 protein, indicating that this rice-derived SS1 protein could be a promising candidate as an alternative HBV vaccine for preventing hepatitis B.     

Expression and characterization of chimeric hepatitis B surface antigen particles carrying preS epitopes.

Many studies have provided evidence that hepatitis B surface antigen (HBsAg) including preS1 and preS2 sequences could be an ideal candidate for a new hepatitis B virus (HBV) vaccine with higher efficacy. However, the large (L) protein containing the entire preS region expressed in mammalian cells is not efficiently assembled into particles and secreted. Here we report an alternative approach to include the dominant epitopes of preS1 and preS2 to the small (S) protein as fusion proteins by the recombinant DNA technology. Three fusion proteins containing preS2(120-146) and preS1(21-47) at the N-terminus and/or truncated C-terminus of S protein were expressed using the recombinant vaccinia virus system. All these fusion proteins were efficiently secreted in the particulate form, and displayed S, preS1 and/or preS2 antigenicity. Further analysis showed that these chimeric HBsAg particles elicited strong antibody responses against S, preS1 and preS2 antigens in BALB/c mice, suggesting that they could be promising candidates for a new recombinant vaccine to induce broader antibody response required for protection against hepatitis B viral infection.     

Expression of overlapping PreS1 fragment recombinant proteins for the determination of immunogenic domains in HBsAg PreS1 region

The virion of the hepatitis B virus (HBV) is a sphericalparticle of 42-nm diameter whose envelope contains threerelated surface glycoproteins called the large (L), middle(M) and small (S) proteins.All these proteins are expressedfrom one open reading frame using three in-frame startsites [1]. The L protein is the translation product of thewhole open reading frame. The M protein lacks the N-terminal amino acid residue 108–119 of Lprotein (the preS1sequence), and the S protein lacks the N…     

A flexible peptide linker enhances the immunoreactivity of two copies HBsAg preS1 (21-47) fusion protein

PreS1 (21-47) region of HBV large surface protein is hepatocyte receptor binding site and the anti-preS1 (21-47) antibody possesses the virus-neutralizing activity and protective effect. It is important to obtain the peptide with higher immunoreactivity on a large scale for detecting the anti-preS1 (21-47) antibody in the sera from HBV infected patients and future vaccine recipients. The expression vector pGEX SLS, which expressed two copies of the preS1 (21-47) peptide connected by a flexible linker (Gly4Ser3) fused to glutathione S-transferase (GST), was constructed. The fusion protein, named GST-SLS, was highly expressed in E. coli and purified by affinity chromatography. Ninety milligrams purified protein can be obtained from 1l of culture. The data in ELISA analysis showed that the immunoreactivity of GST-SLS was enhanced significantly in comparison with GST-S II, a GST fusion protein with two copies preS1 (21-47) linked directly; GST-S I, another GST fusion protein with one copy preS1 (21-47) and preS1 (21-47) synthesized peptide. In addition, GST-SLS has been tried to use in detecting anti-preS1 (21-47) antibody in the sera from HBV infected patients and a satisfied result was gained. Therefore, GST-SLS may have potential to be developed into a new kit for diagnosis and prognosis of hepatitis B (HB) patients.     

A modified hepatitis B surface antigen carrying both preS1 and preS2 epitopes

ＴｈｅｅｎｖｅｌｏｐｅｐｒｏｔｅｉｎｏｆｈｅｐａｔｉｔｉｓＢｖｉｒｕｓ(ＨＢＶ)ｃｏｎｓｉｓｔｓｏｆｔｈｒｅｅｐｒｏｔｅｉｎｓ:ｓｍａｌｌ(Ｓ),ｍｉｄｄｌｅ(Ｍ)ａｎｄｌａｒｇｅ(Ｌ)[1].ＴｈｅＳｐｒｏｔｅｉｎｃａｒｒｉｅｓａｌｌｔｈｅｉｎｆｏｒｍａｔｉｏｎｒｅｑｕｉｒｅｄｆｏｒｃｅｌｌｕｌａｒｌｉｐｉｄｓｍｏｂｉｌｉｚａｔｉｏｎ,ｓｕｂｖｉｒａｌｐａｒｔｉｃｌｅｆｏｒｍａｔｉｏｎａｎｄｓｅｃｒｅｔｉｏｎ.Ｉｔｈａｓｂｅｅｎｓｕｃｃｅｓｓｆｕｌｌｙｄｅｖｅｌｏｐｅｄａｓａｃａｒｒｉｅｒｔｏｅｘｐｒｅｓｓｆ…     

Potato Virus Y-Like Particles as a New Carrier for the Presentation of Foreign Protein Stretches

Virus-like particle (VLP) technology represents a promising approach for the creation of efficient vaccines and materials for use in nanotechnological applications. For construction of a new carrier for foreign protein sequences, the coat protein (CP) gene from potato virus Y (PVY) was cloned and expressed in Escherichia coli cells. The PVY CP self-assembles into PVY-like particles, as demonstrated by electron microscopy analysis of purified VLP preparations. The PVY CP with an N-terminal insertion of a foreign epitope (preS1) or of a whole protein (rubredoxin) retains its ability to form filamentous particles, whereas adding a foreign sequence to the C-terminus of the PVY CP generates mostly unstructured protein aggregates. This new filamentous plant virus-derived VLP carrier accommodates a foreign protein sequence that is up to 71 amino acids in length on the VLP surface and can be produced in E. coli in preparative amounts. The PVY CP VLPs are stable in physiological conditions, but they are sensitive to EDTA, high salt, and extreme pH. The presence of the preS1 epitope decreases the stability of the chimeric PVY CP particles at elevated temperatures. Mice that are immunized with chimeric PVY CP particles carrying preS1 epitopes exhibit a strong anti-preS1 immune response, even in the absence of adjuvants.     

Molecular analysis of the modulatory factors of the response to HBsAg in mice as an approach to HBV vaccine enhancement

Abstract Mice were injected with immune complexes containing the recombinant hepatitis B surface antigen (HBsAg) vaccine (S + preS2) bound to different monoclonal antibodies (mAbs), in order to determine whether an enhancement of the response to a human vaccine could be obtained and observed. Enhancement and indifference were observed, as well as a decrease in immunogenicity. N relationship could be established between any effect and affinity or isotypy of the bound mAbs. The preS2 region was rendered more immunogenic when an IgG2a mAb was bound to the S region of the HBsAg. The response to the S region was not modulated, whereas immunogenicity of the preS2 collinear region was decreased by antibody shielding. The mAb which was the most efficient as an enhancer of the antibody response also increased binding of the complexed immunogen to antigen presenting cells. The binding of a human mAb to the sole S region, but not to the preS2 region, should be tested as a potentiating agent of the anti-preS2 human immune response.